Recombinant Protein Production News and Research

RSS

Researchers investigate effects of non-allergenic components of pollen on allergy sufferers

Up to now, research into pollen allergies has largely focused on allergens - those components of pollen that trigger hypersensitivity reactions. When it comes into contact with the nasal mucous membrane, however, pollen releases a host of other substances in addition to allergens.

13 May 2016

Small peptide TAxI holds promise for carrying biologic drugs into spinal cord

A small peptide dubbed TAxI is living up to its name. Recent studies show it to be an effective vehicle for shuttling functional proteins, such as active enzymes, into the spinal cord after a muscle injection.

17 Feb 2016

New drug approved by FDA for treatment of von Willebrand disease

"VONVENDI [von Willebrand factor (Recombinant)]", the new drug from Baxalta Incorporated, a global biopharmaceutical company recently spun off from Baxter International, has just been approved by the United States Food and Drug Administration.

22 Dec 2015

Ipsen, EpiVax partner to create next generation botulinum neurotoxin and TSI therapeutics

Ipsen and the US company EpiVax, Inc. today announced that they have completed a collaborative project that provides a novel approach for creating next generation botulinum neurotoxin (BoNT) and Targeted Secretion Inhibitor (TSI) therapeutics.

27 Oct 2015

Protein Sciences earns Frost & Sullivan 2013 Global New Product Innovation Award

Based on its recent analysis of the influenza vaccines market, Frost & Sullivan recognises Protein Sciences with the 2013 Global New Product Innovation Award. Flublok is the world's first recombinant protein vaccine for the prevention of seasonal influenza disease to gain U.S. FDA approval.

29 Dec 2014

BRI signs license agreement with SOBI for Kineret (anakinra)

Baylor Research Institute, the research arm of the Baylor Scott & White Health, announced that it has signed an agreement with Swedish Orphan Biovitrum AB (Sobi) to non-exclusively license Baylor's patents pertaining to the treatment of Systemic Onset Juvenile Idiopathic Arthritis (SJIA or SOJIA) using interleukin-1 (IL-1) beta antagonists.

6 Dec 2014

New oral biologic medication successfully treats precancerous intestinal inflammation

An oral biologic medication has successfully treated chronic, precancerous inflammation in the intestine, according to results of an animal study authored by an MD/PhD student in the University at Buffalo School of Medicine and Biomedical Sciences.

16 Oct 2014

Research report on biopharmaceutical and vaccine manufacturing markets

The total biopharmaceutical manufacturing market is growing, according to Kalorama Information's report, Biopharmaceutical and Vaccine Production Markets.

24 Sep 2014

Genticel provides update on patents granted in the USA and Asia

Genticel, a French biotechnology company and leading developer of therapeutic vaccines, provides an update on patents that have recently enriched its intellectual property estate.

25 Jul 2014

Delphi Genetics announces new license agreement for use of StabyExpress technology in food industry

Delphi Genetics SA has announced today a new license agreement for the use of the StabyExpress® technology in the food industry. The technology will be used for the production of enzymes for food processing.

17 Jun 2014

Celsion signs definitive asset purchase agreement to acquire EGEN

Celsion Corporation (Celsion) (NASDAQ: CLSN), an oncology drug development company, and EGEN, Inc. (EGEN), a privately-held biopharmaceutical company focused on the development of nucleic acid-based therapeutics for the treatment of cancer and other difficult to treat diseases, today announced the signing of a definitive asset purchase agreement in which Celsion will acquire substantially all of the assets of EGEN, including its Phase Ib DNA-based immunotherapy product candidate EGEN-001 and its therapeutic platform technologies, TheraPlas™ for delivery of DNA and mRNA, TheraSilence™ for delivery of RNA, and RAST™ for Cell Enabled Expression and Secretion of RNA.

10 Jun 2014

Researchers discover new therapeutic approach for hemophilia

Researchers at the UNC School of Medicine and the Medical College of Wisconsin found that a new kind of gene therapy led to a dramatic decline in bleeding events in dogs with naturally occurring hemophilia A, a serious and costly bleeding condition that affects about 50,000 people in the United States and millions more around the world.

12 Dec 2013

Recombinant human prion protein stops propagation of prions, say researchers

Case Western Reserve University researchers today published findings that point to a promising discovery for the treatment and prevention of prion diseases, rare neurodegenerative disorders that are always fatal.

10 Oct 2013

Edimer doses first XLHED-affected neonate in Phase 2 trial of EDI200

Edimer Pharmaceuticals, a biotechnology company focused on developing an innovative therapy for the rare genetic disorder X-linked Hypohidrotic Ectodermal Dysplasia (XLHED), today announced the enrollment and completed dosing of the first XLHED-affected neonate in a Phase 2 trial of EDI200, the company's novel, proprietary, recombinant protein.

9 Oct 2013

Drexel University researchers create molecule that can cause AIDS virus to destroy itself

Pinning down an effective way to combat the spread of the human immunodeficiency virus, the viral precursor to AIDS, has long been challenge task for scientists and physicians, because the virus is an elusive one that mutates frequently and, as a result, quickly becomes immune to medication.

20 Sep 2013

New quick test promises to reduce economic, health burden of syphilis cases in Latin America

Demystifying the chemical processes that create a wine's aroma, and the invaluable potential application of that understanding in winemaking, is the new objective of scientists in Uruguay who, with European partners, also recently sequenced the genome of the high-value Tannat grape, from which "the most healthy of red wines" are fermented.

2 Sep 2013

Athera Transfers Annexin A5 Project To Medirista

...

23 Aug 2013

Athera Transfers Annexin A5 Project To Medirista

...

23 Aug 2013

iBio announces production of vaccine candidate for new H7N9 influenza virus

iBio, Inc. today announced the production of a vaccine candidate for the newly emerged H7N9 influenza virus by an independent third party laboratory using the iBioLaunch platform.

22 May 2013

Glide Pharma awarded contract from Pfenex Inc. to develop a solid formulation of recombinant anthrax vaccine

Glide Pharma® today announced the award of a sub-contract from Pfenex Inc. to develop a solid formulation containing the recombinant Protective Antigen (rPA) from Bacillus anthracis expressed in Pfēnex Expression Technology™ suitable for delivery with the Glide SDI® (solid dose injector). This approach will address two important logistical constraints of the currently available vaccine, namely, long term stability during storage and ease of administration.

30 Apr 2013

Recombinant Protein Production News and Research

Researchers investigate effects of non-allergenic components of pollen on allergy sufferers

Small peptide TAxI holds promise for carrying biologic drugs into spinal cord

New drug approved by FDA for treatment of von Willebrand disease

Ipsen, EpiVax partner to create next generation botulinum neurotoxin and TSI therapeutics

Protein Sciences earns Frost & Sullivan 2013 Global New Product Innovation Award

BRI signs license agreement with SOBI for Kineret (anakinra)

New oral biologic medication successfully treats precancerous intestinal inflammation

Research report on biopharmaceutical and vaccine manufacturing markets

Genticel provides update on patents granted in the USA and Asia

Delphi Genetics announces new license agreement for use of StabyExpress technology in food industry

Celsion signs definitive asset purchase agreement to acquire EGEN

Researchers discover new therapeutic approach for hemophilia

Recombinant human prion protein stops propagation of prions, say researchers

Edimer doses first XLHED-affected neonate in Phase 2 trial of EDI200

Drexel University researchers create molecule that can cause AIDS virus to destroy itself

New quick test promises to reduce economic, health burden of syphilis cases in Latin America

Athera Transfers Annexin A5 Project To Medirista

Athera Transfers Annexin A5 Project To Medirista

iBio announces production of vaccine candidate for new H7N9 influenza virus

Glide Pharma awarded contract from Pfenex Inc. to develop a solid formulation of recombinant anthrax vaccine

Unlocking the Secrets of Multiple Sclerosis Progression: Brain-Immune Cell Communication

Passing on Polycystic Ovary Syndrome: Health risks for male offspring of women with PCOS

Top-Down Proteomics: Bridging the Genotype-to-Phenotype Gap

Latest Life Science News